Origin Sciences

Clinical studies. ORI-01, ORI-02, ORI-03, TRIOMIC.

The NHS’s current approach to colorectal cancer diagnostics places a significant and unnecessary burden on the healthcare system. Colonoscopies are expensive and invasive procedures, with over 80% either normal or identifying no significant disease.

Integrating Seamlessly Into the NHS CRC Pathway. Oricol PreView is designed to integrate seamlessly into the existing NHS colorectal cancer (CRC) diagnostic pathway, enabling earlier assessment, faster decision-making, and more efficient patient flow.

Conducted across four sites in Manchester, ORI-01 enrolled 106 patients, with 66 diagnosed with inflammatory bowel disease (IBD). The study compared rectal mucus calprotectin levels with faecal calprotectin in patients both with and without IBD.

A multi-center trial involving 800 symptomatic patients across four NHS hospitals tested Oricol’s detection of colorectal cancer, confirmed the mucus hypothesis, and assessed patient acceptance while building a biobank of samples.

A study at the Royal Devon & Exeter NHS Hospital evaluates Oricol’s ability to detect colorectal and other gastrointestinal diseases, including 50 retrospective CRC samples and 250 prospective cases of pancreatic, lung adenocarcinoma, and urothelial cancer.

OriCol, manufactured by TOGL, received CE marking under the European Union Medical Device Regulation (MDR 2017/745).

Origin Sciences Partners with Primerdesign to Create Novel Rectal Mucosal Extraction Workflow. Robust DNA extraction supports earlier detection and diagnosis of colorectal cancer and other gastrointestinal diseases.

Over 20 years of research identified rectal mucus as the most effective sample type for diagnosing gastrointestinal conditions, outperforming stool or blood.

Origin Sciences developed a hologenomic approach combining host genetics, epigenetics, and microbiome data to provide a comprehensive view of human health.

Origin operates under an ISO 13485:2016-certified quality management system for medical devices and IVD assays, using a risk-based approach.

section_video.

A cancer trial at a **Community Diagnostic Centre** reduces patient waiting times while developing a new diagnostic test. The initiative, led by an NHS team, advances early cancer detection methods. The project earns recognition with a national award shortlisting.

Aug 2026SaTHNews article

Primerdesign and Origin Sciences collaborate to develop a new workflow for extracting DNA from rectal mucosal samples. The workflow aims to improve early detection and diagnosis of colorectal cancer and other gastrointestinal diseases by enhancing DNA extraction efficiency. This partnership leverages Primerdesign’s expertise in molecular diagnostics and Origin Sciences’ innovations in sample processing.

Mar 2026International Biopharmaceutical IndustryNews article

The NHS’s **Sath** cancer trial is evaluating a new test to detect colorectal cancer and high-risk polyps. Early results contribute to reduced patient waiting times for diagnostic procedures. The initiative aims to streamline early cancer identification in the UK’s public healthcare system.

Mar 2026SaTHNews article

A new funding round expands a colorectal cancer trial aiming to enroll **6,600 patients** by **June 2026**. The initiative builds on existing research efforts to evaluate treatment efficacy in a larger participant group. Researchers seek to accelerate findings that could inform clinical practice.

Dec 2025BBC TechNews article